Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
Rogala, P.; Czarnecka, A.M.; Cybulska-Stopa, B.; Ostaszewski, K.; Piejko, K.; Ziętek, M.; Dziura, R.; Rutkowska, E.; Galus, Ł.; Kempa-Kamińska, N.; Calik, J.; Sałek-Zań, A.; Zemełka, T.; Bal, W.; Kamycka, A.; Świtaj, T.; Kamińska-Winciorek, G.; Suwiński, R.; Mackiewicz, J.; Rutkowski, P. Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. J. Clin. Med. 2022, 11, 2239. https://doi.org/10.3390/jcm11082239
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Calik J, Sałek-Zań A, Zemełka T, Bal W, Kamycka A, Świtaj T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine. 2022; 11(8):2239. https://doi.org/10.3390/jcm11082239
Chicago/Turabian StyleRogala, Paweł, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, Jacek Calik, Agata Sałek-Zań, Tomasz Zemełka, Wiesław Bal, Agnieszka Kamycka, Tomasz Świtaj, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, and Piotr Rutkowski. 2022. "Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence" Journal of Clinical Medicine 11, no. 8: 2239. https://doi.org/10.3390/jcm11082239